• 1
    Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol. Dial. Transplant. 1998; 13: 154159.
  • 2
    Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit. Dial. Int. 2005; 25 (Suppl 4): S19S29.
  • 3
    Korte M, Yo M, Betjes M et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol. Dial. Transplant. 2007; 22: 24122414.
  • 4
    Huddam B, Azak A, Kocak G, Basaran M, Voyvoda A, Durany M. Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. Ren. Fail. 2012; 34: 387389.
  • 5
    Duman S, Bozkurt D, Sipahi S et al. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv. Perit. Dial. 2008; 24: 104110.
  • 6
    Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: Mechanism of action and update on clinical experiences. Perit. Dial. Int. 2009; 29: 252255.